Lentiviral Alpha-Globin Expression Cassettes for Autologous Stem Cell Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for alpha thalassemia are limited by the scarcity of matched donors and high mortality rates associated with allogeneic hematopoietic stem cell transplants, while existing gene editing strategies for beta-thalassemia have not been adapted for alpha-thalassemia.
Innovation Solution
Development of recombinant lentiviral vectors containing an alpha-globin gene expression cassette with specific regulatory elements and promoters to restore alpha-globin production in hematopoietic stem cells, overcoming the limitations of donor availability and transplant complications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If allogeneic hematopoietic stem cell transplant is used to treat alpha thalassemia, then alpha-globin production can be restored, but donor availability is limited and mortality rate is high
Solution Approach 1:
The patent uses the patient's own hematopoietic stem cells (autologous transplantation) that have been genetically modified ex vivo to produce functional alpha-globin chains. This eliminates the need for matched donors while maintaining curative potential, as the modified patient cells are transplanted back to restore hemoglobin production.
Solution Approach 2:
The patent introduces a beta-globin expression cassette as an intermediary genetic element that compensates for the defective alpha-globin genes. This beta-globin cassette serves as a functional substitute, allowing the formation of functional hemoglobin tetramers (alpha2beta2) even when endogenous alpha-globin production is impaired.
2Reliability
If allogeneic hematopoietic stem cell transplant is used to treat alpha thalassemia, then alpha-globin production can be restored, but transplant complications and mortality increase
Solution Approach 1:
By using autologous stem cells from the patient themselves rather than allogeneic donor cells, the patent eliminates complications associated with immune rejection and graft-versus-host disease. The patient's own cells are collected, genetically modified, and transplanted back, avoiding all immunological incompatibility issues.
3Reliability
If gene therapy vectors are designed with multiple regulatory elements, then alpha-globin expression is restored, but vector complexity increases
Solution Approach 1:
The patent divides the gene therapy vector into distinct functional modules: a beta-globin expression cassette containing its own promoter, coding sequence, and polyadenylation signal, integrated into a lentiviral backbone. This modular design allows systematic assembly of regulatory elements while maintaining manageable vector complexity.
Solution Approach 2:
The patent uses a universal beta-globin expression cassette that can function independently of alpha-globin regulatory elements. This cassette contains all necessary components (promoter, coding sequence, polyA signal) to drive functional beta-globin expression, making it a self-contained module that simplifies overall vector design.
Data Source
AI summary
This invention provides vectors (e.g., lentiviral vectors) and expression cassettes for incorporation into vectors for expressing an alpha-globin (α-globin) gene. In certain embodiments method of treatment using such vectors are provided.